Article
Medicine, Research & Experimental
Xinjian Huang, Dongni Shi, Xuxiazi Zou, Xuxia Wu, Shumei Huang, Lingzhi Kong, Muwen Yang, Yunyun Xiao, Boyu Chen, Xiangfu Chen, Ying Ouyang, Libing Song, Yunting Jian, Chuyong Lin
Summary: This study found that BAG2 is significantly upregulated in relapse breast cancer patient tissues, and its high expression is associated with a worse prognosis. BAG2 localizes in mutant p53 aggregates and interacts with misfolded p53 mutants. BAG2 exacerbates the formation of the aggregates and recruits HSP90 to promote their propagation and maintenance, leading to chemoresistance in breast cancer.
Article
Cell Biology
Zhaoze Guo, Han Zhang, Yiming Fu, Junjie Kuang, Bei Zhao, LanFang Zhang, Jie Lin, Shuhui Lin, Dehua Wu, Guozhu Xie
Summary: Cancer-associated fibroblasts (CAFs) are the most common stromal cells in breast cancer, and they play a role in disease progression and chemoresistance. This study found that CAF-derived conditioned media can promote breast cancer cell growth and radioresistance. The secretion of interleukin 6 (IL-6) by CAFs activates the STAT3 signaling pathway, leading to the growth and radioresistance of breast cancer cells. Inhibition of STAT3 or neutralizing IL-6 can block the effects induced by CAFs. In mouse models, the IL-6 receptor monoclonal antibody tocilizumab can reverse CAF-induced growth and radioresistance. Additionally, poor response to radiotherapy in breast cancer is associated with the expression of IL-6 and p-STAT3. These findings highlight the importance of the IL-6/STAT3 signaling pathway as a potential therapeutic target in breast cancer radiotherapy.
CELL DEATH DISCOVERY
(2023)
Article
Biology
Adam Hermawan, Annisa Khumaira, Muthi Ikawati, Herwandhani Putri, Riris Istighfari Jenie, Sonia Meta Angraini, Haruma Anggraini Muflikhasari
Summary: Hesperidin (HES) inhibits breast cancer stem cells (BCSCs) by targeting the p53 protein and is involved in regulating apoptosis and the cell cycle.
COMPUTATIONAL BIOLOGY AND CHEMISTRY
(2021)
Article
Oncology
Monika Aggarwal
Summary: Mutations in the p53 gene are common in human cancers. The synthetic analog 2,2-diphenethyl isothiocyanate (DPEITC) can inhibit the growth of various subtypes of breast cancer cells by rescuing mutant p53 and inducing apoptosis. This study also demonstrates the suppression of chemoresistance-related proteins by DPEITC and its synergistic effect with chemotherapy drugs.
Article
Biochemistry & Molecular Biology
Changwon Yang, Jisoo Song, Sunjae Hwang, Jungil Choi, Gwonhwa Song, Whasun Lim
Summary: The study found that apigenin enhances the inhibitory effect of 5-FU on colorectal cancer cells by suppressing TS expression, promoting apoptosis, and disrupting the cell cycle. Additionally, apigenin increases reactive oxygen species production and intracellular calcium levels, indicating its potential to improve therapeutic efficacy.
Article
Oncology
Beihui Xu, Qi Li, Jianjun Zhang, Fuxiang Chen
Summary: Ajuba, a LIM protein-domain containing protein, acts as a scaffold protein for protein-protein interactions, signalling transduction, and genes transcription. It is highly expressed in colorectal cancer (CRC) tissues, but its specific molecular function in CRC progression remains unclear. Ajuba was found to form a complex with p53 and MDM2, promoting p53 degradation and negatively regulating p53 expression and activity. Chemotherapeutic drugs induced Ajuba expression, which was dependent on the presence of p53.
MOLECULAR ONCOLOGY
(2023)
Article
Oncology
Jie Jiang, Li Gao, Yongting Lan, Yang Wang, Peiqing Zhao
Summary: Previous studies have shown that TIPE1 acts as a tumor suppressor gene in several tumor types, but in cervical cancer, it promotes proliferation by inhibiting p53 activity, suppressing cell apoptosis, and facilitating chemoresistance in a p53-dependent manner. This suggests that TIPE1 plays a crucial role in the transition from chemosensitivity to chemoresistance and could be a potential target for cervical cancer chemotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Pharmacology & Pharmacy
Shun Ying Quah, Charng Choon Wong, Hui Chyn Wong, Kok Lian Ho, Nizar Abdul Manan, Pran Kishore Deb, Sreenivasa Rao Sagineedu, Johnson Stanslas
Summary: The study revealed that acquired chemoresistance to SRJ09 and SRJ23 in colon and prostate cancer cells may be attributed to alterations in the expression of genes related to the PI3K and autophagy pathways.
TOXICOLOGY AND APPLIED PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Seyedeh Tayebeh Ahmadpour, Charlotte Orre, Priscila Silvana Bertevello, Delphine Mirebeau-Prunier, Jean-Francois Dumas, Valerie Desquiret-Dumas
Summary: This review highlights the importance of long noncoding RNAs (lncRNAs) in breast cancer chemoresistance. LncRNAs regulate multiple pathways involved in breast cancer development and treatment response. Understanding these mechanisms in detail may improve the clinical outcomes for breast cancer patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Zhi-Min Deng, Wei Hu, Fang-Fang Dai, Meng-Qin Yuan, Min Hu, Yan-Xiang Cheng
Summary: A prognostic model based on immune and chemosensitivity-related gene pairs was constructed and validated in breast cancer patients, revealing close associations with survival rate, clinical characteristics, tumor mutation burden, immune checkpoints, and response to chemotherapeutic drugs. The model demonstrated predictive capacity as an independent factor and was found to be more accurate than any single factor, suggesting potential practical implications.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Stella C. Ogbu, Samuel Rojas, John Weaver, Phillip R. Musich, Jinyu Zhang, Zhi Q. Yao, Yong Jiang
Summary: Breast cancer is a prevalent cancer in women, and therapeutic resistance to chemotherapy is a major challenge in improving the treatment outcomes. A protein kinase called DSTYK has been found to play a crucial role in promoting chemoresistance in breast cancer cells, particularly in triple-negative breast cancer. This discovery provides valuable insights and lays the foundation for developing new strategies targeting DSTYK to enhance the efficacy of TNBC therapy.
Article
Oncology
Angel C. Y. Yu, Yi-Jye Chern, Peter Zhang, Clarissa C. Pasiliao, Mahbuba Rahman, George Chang, Jianhua Ren, Isabella T. Tai
Summary: NPM1 is frequently overexpressed in colorectal cancer (CRC) and correlates with prognosis and sensitivity to chemotherapy. Inhibition of NPM1 enhances chemosensitivity of CRC cells through AKT pathway-mediated apoptosis. Suppressing NPM1 can attenuate tumor growth and restore chemosensitivity in CRC cells.
CANCER BIOLOGY & THERAPY
(2021)
Review
Medicine, Research & Experimental
Paras Famta, Saurabh Shah, Dharmendra Kumar Khatri, Santosh Kumar Guru, Shashi Bala Singh, Saurabh Srivastava
Summary: Breast cancer is the leading cause of mortality in females globally, with tumor derived exosomes playing a significant role in its pathophysiology and management; exosomes are involved in BC metastasis, immunosuppression, migration, dormancy, and chemo-resistance; liquid biopsies analyzing blood circulating exosomes for early detection of BC show promise, although there may be challenges in translating exosomes based technologies to the market.
Article
Oncology
Hui Wang, Haibo Xu, Wei Chen, Mei Cheng, Li Zou, Qin Yang, Chi Bun Chan, Hao Zhu, Ceshi Chen, Jianyun Nie, Baowei Jiao
Summary: The study reveals that Rab13 is highly expressed in breast CSCs and its depletion can suppress breast cancer cell stemness, tumorigenesis, and chemoresistance by controlling the membrane translocation of CXCR1/2, establishing a supportive BCSC niche. Targeting the Rab13-mediated BCSC niche with bardoxolone-methyl prevents BCSC stemness in vitro and in vivo, providing a potential therapeutic strategy for disrupting the BCSC niche.
Article
Cell Biology
Natalia B. B. Fernandez, Sofia M. Sosa, Justin T. T. Roberts, Maria S. Recouvreux, Luciana Rocha-Viegas, Jessica L. L. Christenson, Nicole S. S. Spoelstra, Facundo L. L. Couto, Ana R. R. Raimondi, Jennifer K. K. Richer, Natalia Rubinstein
Summary: Triple negative breast cancer (TNBC) is an aggressive subtype without effective targeted therapies. Chemotherapy-resistant cancer cells with stem-like properties may repopulate the tumor. Androgen receptor (AR) inhibition can decrease CSC and tumor initiation. RUNX1 correlates with poor prognosis in TNBC and is regulated by AR. The study found that AR binds to RUNX1 regulatory regions, and inhibition of RUNX1 reduces CSC markers and enhances chemotherapy sensitivity.
Article
Oncology
Liv B. Gansmo, Pal Romundstad, Einar Birkeland, Kristian Hveem, Lars Vatten, Stian Knappskog, Per Eystein Lonning
Article
Oncology
Inger Marie Loes, Heike Immervoll, Halfdan Sorbye, Jon-Helge Angelsen, Arild Horn, Stian Knappskog, Per Eystein Lonning
INTERNATIONAL JOURNAL OF CANCER
(2016)
Editorial Material
Oncology
Mitch Dowsett, Per E. Lonning, Nancy E. Davidson
JOURNAL OF CLINICAL ONCOLOGY
(2016)
Editorial Material
Biochemistry & Molecular Biology
Per Eystein Lonning
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2016)
Article
Oncology
Liv B. Gansmo, Merete Bjornslett, Mari Kylleso Halle, Helga B. Salvesen, Anne Dorum, Einar Birkeland, Kristian Hveem, Pal Romundstad, Lars Vatten, Per Eystein Lonning, Stian Knappskog
Article
Oncology
Liv B. Gansmo, Lars Vatten, Pal Romundstad, Kristian Hveem, Brid M. Ryan, Curtis C. Harris, Stian Knappskog, Per E. Lonning
Article
Oncology
Mahesh Tambe, Sofia Pruikkonen, Jenni Maki-Jouppila, Ping Chen, Bente Vilming Elgaaen, Anne Hege Straume, Kaisa Huhtinen, Olli Carpen, Per Eystein Lonning, Ben Davidson, Sampsa Hautaniemi, Marko J. Kallio
Article
Genetics & Heredity
Anita Sveen, Inger Marie Loes, Sharmini Alagaratnam, Gro Nilsen, Maren Holand, Ole Christian Lingjaerde, Halfdan Sorbye, Kaja Christine Graue Berg, Arild Horn, Jon-Helge Angelsen, Stian Knappskog, Per Eystein Lonning, Ragnhild A. Lothe
Article
Biochemistry & Molecular Biology
Marianne Hauglid Flageng, Alexey Larionov, Jurgen Geisler, Stian Knappskog, Wenche S. Prestvik, Geir Bjorkoy, Peer Kare Lilleng, J. Michael Dixon, William R. Miller, Per Eystein Lonning, Gunnar Mellgren
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
(2017)
Editorial Material
Biochemical Research Methods
Per E. Lonning
Article
Multidisciplinary Sciences
Reham Helwa, Liv B. Gansmo, Pal Romundstad, Kristian Hveem, Lars Vatten, Brid M. Ryan, Curtis C. Harris, Per E. Lonning, Stian Knappskog
SCIENTIFIC REPORTS
(2016)
Article
Oncology
Line Pedersen, Pouda Panahandeh, Muntequa I. Siraji, Stian Knappskog, Per Eystein Lonning, Ruth Gordillo, Philipp E. Scherer, Anders Molven, Knut Teigen, Nils Halberg
Article
Endocrinology & Metabolism
Bjorn-Erik Bertelsen, Kristin Viste, Thomas Helland, Magnus Hagland, Havard Soiland, Jurgen Geisler, Tone Hoel Lende, Per Eystein Lonning, Jorn Sagen, Gunnar Mellgren, Bjorg Almas
Summary: This study developed a liquid chromatography-tandem mass spectrometry (MS/MS) method for simultaneous measurement of serum levels of third-generation aromatase inhibitors (AIs) and ultra-low levels of estrogens. The method is highly valuable for studying drug efficacy and compliance.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Bjorn-Erik Bertelsen, Ralf Kellmann, Kristin Viste, Anne Turid Bjornevik, Hans Petter Eikesdal, Per Eystein Lonning, Jorn Sagen, Bjorg Almas
JOURNAL OF THE ENDOCRINE SOCIETY
(2020)
Article
Oncology
Stian Knappskog, Beryl Leirvaag, Liv B. Gansmo, Pal Romundstad, Kristian Hveem, Lars Vatten, Per E. Lonning
HEREDITARY CANCER IN CLINICAL PRACTICE
(2016)
Article
Oncology
Andra S. Martinikova, Miroslav Stoyanov, Anna Oravetzova, Yannick P. Kok, Shibo Yu, Jana Dobrovolna, Pavel Janscak, Marcel van Vugt, Libor Macurek
Summary: Oncogene-induced replication stress is a major cause of genome instability in cancer cells. This study reveals that increased activity of PPM1D exacerbates replication stress caused by cyclin E1 overexpression, leading to abnormal cell cycle progression and accumulation of DNA copy number alterations. Pharmacological inhibition of PPM1D can alleviate replication stress-induced genome instability.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Alamelu G. Bharadwaj, Meghan E. McLean, Margaret L. Dahn, Hannah F. Cahill, Marie-Claire D. Wasson, Raj Pranap Arun, Olivia L. Walker, Brianne M. Cruickshank, Wasundara Fernando, Jaganathan Venkatesh, Penelope J. Barnes, Gillian Bethune, Gregory Knapp, Lucy K. Helyer, Carman A. Giacomantonio, David M. Waisman, Paola Marcato
Summary: ALDH1A3 regulates the plasminogen activation pathway to promote breast cancer metastasis. Co-expression of ALDH1A3 and tPA is associated with TNBC subtype, high tumor grade, and recurrent metastatic disease.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Nayela N. Chowdhury, Yi Yang, Ananya Dutta, Michelle Luo, Zimu Wei, Sara R. Abrahams, Alexey S. Revenko, Fenil Shah, Lindsey A. Miles, Robert J. Parmer, Bas de Laat, Alisa S. Wolberg, James P. Luyendyk, Melissa L. Fishel, Matthew J. Flick
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal metastatic disease associated with robust activation of the coagulation and fibrinolytic systems. Primary fibrinolytic protease plasminogen promotes PDAC tumor growth and metastatic potential through engaging plasminogen receptors on tumor cells.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Nuria Gendrau-Sanclemente, Agnes Figueras, Kristina Gracova, Alvaro Lahiguera, Elisenda Alsina-Sanchis, Juan A. Marin-Jimenez, August Vidal, Xavier Matias-Guiu, Sergi Fernandez-Gonzalez, Marc Barahona, Lola Marti, Jordi Ponce, Francesc Vinals
Summary: High-grade serous ovarian cancer (HGSOC), the deadliest gynecological malignancy, spreads through transcoelomic dissemination. This study reveals that platelet-derived growth factor receptor beta (PDGFRβ) is essential for the formation of tumorspheres in HGSOC. Inhibition of PDGFRβ blocks the clustering of ovarian cancer cells and prevents peritoneal dissemination.
MOLECULAR ONCOLOGY
(2024)
